Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects

Area of Science:

• Oncology
• Molecular Biology
• Urology

Background:

• Bladder cancer management remains challenging despite treatment advances.
• Superficial and invasive bladder cancers require effective therapeutic options.
• Gene-targeted therapies are emerging for cancer treatment.

Purpose of the Study:

• To review recent advances in antisense oligodeoxynucleotide (ASO) therapy for bladder cancer.
• To summarize ASO's role in targeting genes crucial for bladder cancer progression and recurrence.
• To discuss the potential of ASO therapy as an alternative to conventional treatments.

Main Methods:

• Literature review of antisense oligodeoxynucleotide therapy in bladder cancer.
• Analysis of studies on gene targets involved in bladder cancer progression.
• Examination of combination therapies involving ASO and conventional treatments.

Main Results:

• ASO therapy targets specific genes implicated in bladder cancer.
• ASO therapy demonstrates synergistic antitumor activity when combined with chemotherapy, radiation, and molecular therapies.
• Evidence supports ASO's efficacy in managing bladder cancer progression and recurrence.

Conclusions:

• Antisense oligodeoxynucleotide therapy is a promising strategy for bladder cancer.
• Combination approaches enhance the antitumor effects of ASO therapy.
• ASO therapy represents a significant alternative to current bladder cancer treatment strategies.